18F-PSMA-1007与18F-氟胆碱PET/CT定位前列腺癌生化复发的III期随机交叉多中心研究
这项前瞻性、开放标签、随机交叉多中心III期研究纳入190例既往接受根治性治疗且疑似复发的前列腺癌患者,均先后接受18F-PSMA-1007 PET/CT与18F-氟胆碱PET/CT。以独立专家组复合标准为真值,18F-PSMA-1007的患者水平正确检出率高于18F-氟胆碱,且更多患者的诊断思维与治疗决策因18F-PSMA-1007而获益。
要点
- 18F-PSMA-1007较18F-氟胆碱提高前列腺癌生化复发病灶的患者水平正确检出率。
- 将不确定病灶计为恶性时正确检出率为0.82对0.65,计为良性时为0.77对0.57。
- 149例诊断思维改变中93例归因于18F-PSMA-1007贡献更多。
核心结论
- 18F-PSMA-1007 PET/CT在前列腺癌复发病灶定位上优于18F-氟胆碱PET/CT。
- 基于18F-PSMA-1007 PET/CT结果的决策制定更有益。
研究设计与样本
- 前瞻性、开放标签、随机交叉多中心III期研究,纳入既往接受根治性治疗且疑似复发的前列腺癌患者190例。
- 102例先接受18F-PSMA-1007 PET/CT,88例先接受18F-氟胆碱PET/CT。
- 所有图像由3名对临床信息设盲的读片者采用3分定性量表独立评估:0=无复发,1=不确定,2=复发。
- 患者随访约6个月,由泌尿外科、放射科与核医学医师组成的独立专家组在设盲PET/CT信息条件下共识确定基于患者与基于区域的复合真值标准。
主要发现
- 将不确定病灶计为恶性时,患者水平总体正确检出率18F-PSMA-1007为0.82,18F-氟胆碱为0.65(P < 0.0001)。
- 将不确定病灶计为良性时,正确检出率18F-PSMA-1007为0.77,18F-氟胆碱为0.57(P < 0.0001)。
- 149例患者报告PET/CT导致诊断思维改变,其中93例18F-PSMA-1007贡献多于18F-氟胆碱。
- 122例患者PET/CT获得充分诊断并使患者获益,其中88例18F-PSMA-1007贡献多于18F-氟胆碱。
关键数值与推荐
- 主要终点达标,患者水平正确检出率以独立专家组复合真值标准为参照。
- 图像判读采用3分定性量表:0=无复发,1=不确定,2=复发。
临床怎么用
- 原文结论认为18F-PSMA-1007 PET/CT在前列腺癌复发病灶定位上优于18F-氟胆碱PET/CT,基于前者的决策制定更有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to compare 18F-PSMA-1007 PET/CT and 18F-fluorocholine PET/CT for the localization of prostate cancer (PCa) biochemical recurrence. Methods: This prospective, open-label, randomized, crossover multicenter study included PCa patients with prior definitive therapy and suspected PCa recurrence. All men underwent both 18F-PSMA-1007 PET/CT and 18F-fluorocholine PET/CT (102 received 18F-PSMA-1007 PET/CT first and 88 received 18F-fluorocholine PET/CT first). All images were assessed independently by 3 readers masked to all clinical information using a 3-point qualitative scale (0 = no recurrence, 1 = undetermined, and 2 = recurrence). Patients were monitored for approximately 6 mo. An independent panel with a urologist, radiologist, and nuclear physician reviewed all clinical data, including imaging and response to therapy, but were masked regarding PET/CT information; acting in consensus, they determined a patient-based and region-based composite standard of truth for PCa lesions. The "correct detection rates" for PCa lesions on a patient basis for each radiopharmaceutical were compared for the 3 readers individually and for the "average reader." Secondary objectives included determining whether PET/CT findings affected diagnostic thinking (impact of a test result on posttest vs. pretest probability of a correct diagnosis), therapeutic decision making (description and quantification of impact of diagnostic information gained with both radiopharmaceuticals on patient management), and adequacy of management changes. Results: A total of 190 patients were included. The primary endpoint was met. The overall correct detection rates were 0.82 for 18F-PSMA-1007 and 0.65 for 18F-fluorocholine (P < 0.0001) when undetermined findings were considered positive for malignancy and 0.77 and 0.57, respectively (P < 0.0001), when undetermined findings were considered negative for malignancy. A change in diagnostic thinking due to PET/CT was reported in 149 patients; 18F-PSMA-1007 contributed more than 18F-fluorocholine in 93 of these patients. In 122 patients, PET/CT led to an adequate diagnosis that benefited the patient; 18F-PSMA-1007 contributed more than 18F-fluorocholine in 88 of these patients. Conclusion: 18F-PSMA-1007 PET/CT is superior to 18F-fluorocholine PET/CT for the localization of PCa recurrence. Decision making was more beneficial when based on 18F-PSMA-1007 PET/CT results.
引用
- Olivier P, Giraudet AL, Skanjeti A, et al. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. J Nucl Med. 2022. PMID: 36418170. doi:10.2967/jnumed.122.264743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。